TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

AZURITY

CardiovascularOncologyNeurology
Specialty

AZURITY is a specialty pharmaceutical company focused on Cardiovascular, Oncology, Neurology. Key products include FIRVANQ KIT.

1964
Since
47
Drugs
-
Trials
31
Approved (2yr)

Key Drugs

EPRONTIA
topiramate
CNS
AMPA/kainate receptor 5 indications · 2021
FIRVANQ KIT
vancomycin hydrochloride
5 indications · 2018
FLEQSUVY
baclofen
CNS
GABA-B receptor 4 indications · 2022
KATERZIA
amlodipine benzoate
Cardiovascular
Calcium channel 3 indications · 2019
JAVADIN
clonidine hydrochloride
Cardiovascular
alpha-adrenoreceptors 3 indications · 2025

Recent Activity

ARYNTA 2025-12-22
Labeling
SUPREP BOWEL PREP KIT 2025-11-18
Labeling
DANZITEN 2025-11-14
Labeling
DEXTROAMPHETAMINE SULFATE 2025-10-28
Manufacturing (CMC)
JAVADIN 2025-10-23
Type 3 - New Dosage Form
TRIPTODUR KIT 2025-09-23
Labeling
DEXTROAMPHETAMINE SULFATE 2025-07-16
Manufacturing (CMC)
AZMIRO 2025-07-11
Labeling
APREPITANT 2025-07-03
Labeling
MYHIBBIN 2025-06-27
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 41%
10 drugs
Oncology 25%
6 drugs
Neurology 17%
4 drugs Phase 1: 1
Metabolic 12%
3 drugs
Infectious Disease 4%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Cardiovascular, Metabolic
Novo Nordisk big-pharma
Metabolic, Oncology, Cardiovascular, Infectious Disease, Neurology
GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Oncology
Baxter specialty
Infectious Disease, Cardiovascular, Oncology